Document is current
Any future updates will be listed below
-
Authors
van Ruitenbeek, Niels J.
Uijen, Maike J. M.
Driessen, Chantal M. L.
van Rijk, Maartje C.
Peters, Steffie M. B.
Privé, Bastiaan M.
Verhaegh, Gerald W.
van Engen-van Grunsven, Adriana C. H.
Gotthardt, Martin
Nagarajah, James
van Herpen, Carla M. L. https://orcid.org/0000-0001-5130-5451
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (11807)
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 9 June 2025
First Online: 15 July 2025
Declarations
:
: This study was performed in adherence with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Medical Review Ethics Committee Arnhem-Nijmegen, the Netherlands (NL71139.091.19). Written informed consent was obtained from all the participants before study enrolment.
: Not applicable.
: James Nagarajah has received research grants from ABX and Novartis, and has received consulting and teaching fees from ITM, POINT biopharma, CURIUM, Novartis, and Bayer. Carla van Herpen has been member of advisory boards for Bayer, Bristol-Myers Squibb, Elevar, Ipsen, MSD, and Regeneron, and has received research grants from Astra Zeneca, Bristol-Myers Squibb, MSD, Merck, Ipsen, Novartis, and Sanofi. The other authors declare no competing interests.
